Correlation of Cancer Stem Cell Markers and Immune Cell Markers in Resected Non-small Cell Lung Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2017 Nov 22

PMID 29158791

Citations 9

Authors

Zhaoqin Huang

Haining Yu

Jianbo Zhang

Haiyan Jing

Wanqi Zhu

Xiaolin Li

Lingling Kong

Ligang Xing

Jinming Yu

Xiangjiao Meng

Affiliations

Soon will be listed here.

Abstract

Recent studies confirmed that immunotherapy showed prominent efficacy in non-small cell lung cancer (NSCLC). Cancer stem cells/cancer initiating cells are resistant to anticancer treatment. The purpose of the study was to analyze the correlation of cancer stem cells/cancer initiating cells and tumor-infiltrating immune cells in NSCLC. CD133, octamer 4 (OCT-4), CD8, CD56, human leukocyte antigen (HLA) class I and programmed death ligand-1 (PD-L1) were assessed in 172 resected NSCLC samples. The staining was analyzed and scored by the pathologist who was blinded to the clinical pathological data of the patients. High CD8+ T cell infiltration was correlated significantly with squamous cell carcinoma histology (p=0.008). High PD-L1 expression (≥10%) was associated with high tumor status (p=0.043). Pearson's correlation test showed that CD56+ cells were negatively correlated with CD133 expression (r=-0.361, p<0.001) and weakly correlated with negative OCT-4 expression (r=-0.180, p=0.018). There was a strong positive correlation between CD8 and HLA class I (r=0.573, p<0.001). In the survival analysis, high CD8+ T cell infiltration is an independent predictor of improved disease-free survival and overall survival. Patients with low CD133 expression and high CD56 expression had a longer overall survival than those with high CD133 expression and/or low CD56 expression (p=0.013). There is a negative correlation between CD56+ cells and cancer stem cell markers. This correlation may confirm the possibility that natural killer cells can target CD133+ cancer stem cells/cancer initiating cells in non-small cell lung cancer.

Citing Articles

Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG).

Lyu C, Wang L, Stadlbauer B, Noessner E, Buchner A, Pohla H Cancers (Basel). 2022; 14(17).

PMID: 36077742 PMC: 9454898. DOI: 10.3390/cancers14174200.

Lung Cancer Stem Cells and Their Clinical Implications.

Rowbotham S, Goruganthu M, Arasada R, Wang W, Carbone D, Kim C Cold Spring Harb Perspect Med. 2021; 12(4).

PMID: 34580078 PMC: 9121890. DOI: 10.1101/cshperspect.a041270.

Correlation between cancer stem cells (CSCs) and tumor-infiltrating lymphocytes (TILs): do TILs interact with CSCs in non-small cell lung cancer?.

Ling M, Yang X Ann Transl Med. 2020; 8(15):914.

PMID: 32953714 PMC: 7475387. DOI: 10.21037/atm-20-1556.

Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A Front Immunol. 2020; 11:1280.

PMID: 32849491 PMC: 7426526. DOI: 10.3389/fimmu.2020.01280.

Interface of cancer stem cells and cancer immunity.

Kinoshita T, Kawakami Y Ann Transl Med. 2020; 8(13):810.

PMID: 32793655 PMC: 7396253. DOI: 10.21037/atm.2020.04.08.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N . Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016; 55:7-14. DOI: 10.1016/j.ejca.2015.11.020. View

Perea F, Bernal M, Sanchez-Palencia A, Carretero J, Torres C, Bayarri C . The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. Int J Cancer. 2016; 140(4):888-899. DOI: 10.1002/ijc.30489. View

Marincola F, Jaffee E, Hicklin D, Ferrone S . Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 1999; 74:181-273. DOI: 10.1016/s0065-2776(08)60911-6. View

Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R . Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol. 2013; 190(5):2381-90. DOI: 10.4049/jimmunol.1201542. View

Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S . HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007; 98(9):1424-30. PMC: 11159758. DOI: 10.1111/j.1349-7006.2007.00558.x. View

Cortes-Dericks L, Galetta D, Spaggiari L, Schmid R, Karoubi G . High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur J Cardiothorac Surg. 2012; 41(6):e173-81. DOI: 10.1093/ejcts/ezs170. View

Hald S, Bremnes R, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H . CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer. 2013; 80(2):209-15. DOI: 10.1016/j.lungcan.2012.12.026. View

Lundholm L, Haag P, Zong D, Juntti T, Mork B, Lewensohn R . Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis. 2013; 4:e478. PMC: 3563998. DOI: 10.1038/cddis.2012.211. View

10.

Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka K, Kikuchi E . CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 2013; 19(2):254-9. DOI: 10.1007/s10147-013-0541-x. View

11.

Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A . Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2007; 15(3):504-14. DOI: 10.1038/sj.cdd.4402283. View

12.

Fernandez L, Valentin J, Zalacain M, Leung W, Patino-Garcia A, Perez-Martinez A . Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett. 2015; 368(1):54-63. DOI: 10.1016/j.canlet.2015.07.042. View

13.

Ghosh G, Lian X, Kron S, Palecek S . Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer. 2012; 12:95. PMC: 3364915. DOI: 10.1186/1471-2407-12-95. View

14.

Zhong B, Lin Y, Lai Y, Zheng F, Zheng X, Huang R . Relationship of Oct-4 to malignant stage: a meta-analysis based on 502 positive/high Oct-4 cases and 522 negative/low case-free controls. Oncotarget. 2015; 7(2):2143-52. PMC: 4811523. DOI: 10.18632/oncotarget.5737. View

15.

Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y . Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006; 94(2):275-80. PMC: 2361103. DOI: 10.1038/sj.bjc.6602934. View

16.

Niwa H, Miyazaki J, Smith A . Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000; 24(4):372-6. DOI: 10.1038/74199. View

17.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

18.

Volonte A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L . Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2013; 192(1):523-32. PMC: 8744948. DOI: 10.4049/jimmunol.1301342. View

19.

Sourisseau T, Hassan K, Wistuba I, Penault-Llorca F, Adam J, Deutsch E . Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?. J Thorac Oncol. 2013; 9(1):7-17. DOI: 10.1097/JTO.0000000000000028. View

20.

Jordan C . Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004; 16(6):708-12. DOI: 10.1016/j.ceb.2004.09.002. View